Action DAWN DAY ONE BIOPHARMACEUTICALS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Day One Biopharmaceuticals, Inc.

Actions

DAWN

US23954D1090

Temps réel estimé Cboe BZX
Autres places de cotation
 21:14:14 10/06/2024 		Varia. 5j. Varia. 1 janv.
12,58 USD -1,45 % Graphique intraday de Day One Biopharmaceuticals, Inc. -4,40 % -13,70 %
30/05 Day One Biopharmaceuticals vend son bon d'examen prioritaire pour 108 millions de dollars MT
20/05 BrightSpring Health Services déclare qu'Onco360 a été choisi comme partenaire pharmaceutique pour Ojemda MT

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Day One Biopharmaceuticals Sells Priority Review Voucher for $108 Million
Day One Announces Sale of Priority Review Voucher for $108 Million
BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Day One Reports First Quarter 2024 Financial Results and Corporate Progress
North American Morning Briefing : Stock Futures -2-
Day One Biopharmaceuticals Insider Sold Shares Worth $1,081,191, According to a Recent SEC Filing
Day One Biopharmaceuticals Insider Sold Shares Worth $1,415,707, According to a Recent SEC Filing
North American Morning Briefing : Investors Brace -2-
Day One Biopharmaceuticals : Corporate Presentation - April 2024
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor
Day One's OJEMDA (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma
Day One Biopharmaceuticals Shares Rise; FDA Issues Accelerated Approval for Pediatric Low-Grade Glioma Treatment
Day One Biopharmaceuticals Drug Tovorafenib Gets FDA Accelerated Approval
Day One Biopharmaceuticals Insider Sold Shares Worth $322,166, According to a Recent SEC Filing
Day One Biopharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress
Day One Biopharmaceuticals, Inc. Announces Executive Changes
Day One Announces Two New Appointments to Board of Directors
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action DAWN
  4. Actualités Day One Biopharmaceuticals, Inc.
  5. Autres langues